Össur reports 23% EBITDA

3rd Q 2009

  • Sales USD 84 million
  • Strong prosthetics sales, growing 11%
  • EBITDA margin 23%
  • Net profit 7% of sales
  • Second generation of RHEO KNEE extremely well received
  • GPO contract in the US
  • Listing on NASDAQ OMX Copenhagen

Jon Sigurdsson, President & CEO, comments: 

“We are quite satisfied with the results for the quarter. Our business continues to be successful and profitable. Prosthetics sales exceeded our expectations, and recent product upgrades and the new generation of RHEO KNEE have been well received by the market. This further establishes the acceptance of the Bionic products. Sales of bracing and supports products are stabilizing and we are confident that we will see a turnaround in sales in this segment in the coming quarters.” 

 Financial Statement 3Q Össur.pdf

 

  Press Release Össur.pdf 

  • Eyrir becomes the largest shareholder in The Kingfish Company

    On the 12 May, Kingfish announced a strategic financial restructuring, which upon completion will result…

  • New Board elected at Eyrir Invest

    At a shareholders' meeting of Eyrir Invest hf. held on 8 April, 2025, a new…

  • Eyrir invest history

    At the Annual General Meeting of Eyrir Invest on 27 March 2025, the Board’s proposal…